Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viactiv is a brand of dietary supplements primarily known for its calcium soft chews designed to support bone health and density. The flagship formulation typically combines calcium carbonate, vitamin D3 (cholecalciferol), and vitamin K1 (phytonadione). Calcium is a critical mineral for maintaining skeletal integrity, while vitamin D3 acts as a Vitamin D receptor (VDR) agonist to enhance intestinal calcium absorption. Vitamin K1 serves as an essential cofactor for the gamma-carboxylation of osteocalcin, a protein necessary for effective bone mineralization. By providing these three synergistic nutrients in a palatable, chewable format, Viactiv aims to improve compliance among individuals at risk for bone loss, such as postmenopausal women. It is primarily indicated as a nutritional supplement to help prevent osteoporosis and maintain bone strength.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Viactiv.